Jakub Kopycinski
LightNews LightNews
banner
jkopy.bsky.social
Jakub Kopycinski
@jkopy.bsky.social
310 followers 1.7K following 14 posts
Vaccine immunologist, Arsenal fan and fatigued rugby dad.
Posts Replies Media Videos
jkopy.bsky.social
Cytokines look “modest”. I can do this all day, but would no-doubt offend people.
October 30, 2025 at 9:37 PM
jkopy.bsky.social
Loving the CD4 vs CD8.
October 30, 2025 at 9:36 PM
jkopy.bsky.social
I see that and raise you this:
October 30, 2025 at 9:35 PM
jkopy.bsky.social
Lemmeguess, belongs to an overconfident medic in the 1st year of their PhD?
October 30, 2025 at 9:30 PM
Reposted by Jakub Kopycinski
sailorrooscout.bsky.social
The study has been published in Science. YES, it is PEER-REVIEWED.
• www.science.org/doi/10.1126/...
• www.scripps.edu/news-and-eve...
ABSTRACT A leading HIV vaccine strategy requires a priming immunogen to induce broadly neutralizing antibody (bnAb) precursors, followed by a series of heterologous boosters to elicit somatic hypermutation (SHM) and produce bnAbs. In two randomized, open-label phase 1 human clinical trials, IAVI-G002 in the United States and IAVI-G003 in Rwanda and South Africa, we evaluated the safety and immunogenicity of mRNA-encoded nanoparticles as priming immunogens (both trials) and first-boosting immunogens (IAVI-G002). The vaccines were generally safe and well tolerated, except 18% of IAVI-G002 participants experienced skin reactions. Priming induced bnAb precursors with substantial frequencies and SHM, and heterologous boosting elicited increased SHM, affinity, and neutralization activity toward bnAb development. The results establish clinical proof of concept that heterologous boosting can advance bnAb-precursor maturation and demonstrate bAb priming in Africa where the HIV burden is highest. FUNDING This work was supported by funding from the Gates Foundation Collaboration for AIDS Vaccine Discovery (CAVIMC INV-007368, CAVIMC INV-036842, CCVIMC INV-007371, VISC INV-008017, INV-032929, CAVD network INV-002916, VxPDC INV-008352, INV-007375, NAC INV-007522, INV-008813, INV-007385 and INV-005175); IAVI (IAVI 167627819, |AVI A0803); the lAVI Neutralizing Antibody Center; the National Institute of Allergy and Infectious Diseases (NIAID) (UM1 Al100663 and UM1 Al144462); the Intramural Research Program of NIAID; the Swedish Research Council (2017-00968); Moderna, Inc.; the U.S. Agency for International Development (USAID) (AID-5 OAA-A-16-00032 and IAVI A11257); and the U.S. President's Emergency Plan for AIDS Relief. Two phase 1 clinical trials tested the first steps of a germline-targeting HIV vaccine strategy to induce broadly neutralizing antibodies (bnAbs). A nanoparticle antigen (multicolored sphere) delivered via mRNA activated immune cells, including bnAb precursor B cells (red) and other B cells (blue). The red cells began producing bnAb precursors (red Y-shapes). In one trial (IAVI G002), a second, distinct nanoparticle antigen (larger multicolored sphere) further guided those precursors toward developing the features of bnAbs. Credit: Scripps Research Fig. S1. Conceptual schematic for germline-targeting vaccine design.
May 16, 2025 at 4:01 PM
jkopy.bsky.social
Are these designated cycle paths? Thinking about taking the family.
May 10, 2025 at 3:44 PM